Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Guardant Health (GH – Research Report) today and set a price target of $45.00. The company’s shares closed yesterday at $26.91.
Arias covers the Healthcare sector, focusing on stocks such as Illumina, Danaher, and Exact Sciences. According to TipRanks, Arias has an average return of -8.2% and a 40.59% success rate on recommended stocks.
Currently, the analyst consensus on Guardant Health is a Strong Buy with an average price target of $43.73, representing a 62.50% upside. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $50.00 price target.
See the top stocks recommended by analysts >>
GH market cap is currently $3.27B and has a P/E ratio of -6.62.
Based on the recent corporate insider activity of 79 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GH in relation to earlier this year. Most recently, in November 2023, Chudova Darya, the CTO of GH bought 4,000.00 shares for a total of $35,200.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Guardant Health (GH) Company Description:
Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
Read More on GH:
- Guardant, Hikma team on cancer screening and genomic profiling tests in MENA
- Guardant Health names Terilyn Juarez Monroe as chief people officer
- Guardant Health sells 3.387M shares at $26.77 in registered direct offering
- Guardant Health announces tentative date of FDA panel review of Shield test
- Guardant Health initiated with neutral view at Guggenheim, here’s why
